Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized
the treatment of a wide variety of malignancies, leading to durable therapeutic responses not …

T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in
resected tumor samples derived from long-surviving patients, and impressive clinical …

Epigenetics has long been recognized as a significant field in biology and is defined as the
investigation of any alteration in gene expression patterns that is not attributed to changes in …

Patients with advanced melanoma that is of low tumor‐associated antigen (TAA) expression
often respond poorly to PD‐1/PD‐L1 blockade therapy. Epigenetic modulators, such as …

Methylation of DNA at CpG sites is the most common and stable of epigenetic changes in
cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by …

Epigenetic mechanisms, which involve DNA and histone modifications, result in the
heritable silencing of genes without a change in their coding sequence. The study of human …

The past few years have seen an explosion of interest in the epigenetics of cancer. This has
been a consequence of both the exciting coalescence of the chromatin and DNA …

Genome-wide DNA hypomethylation occurs in many human cancers, but whether this
epigenetic change is a cause or consequence of tumorigenesis has been unclear. To …